{"id":"W2587305350","doi":"10.1111/jdv.14163","title":"Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis","year":2017,"lang":"en","type":"article","venue":"Journal of the European Academy of Dermatology and Venereology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":67,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre de Recherche Dermatologique du Québec Métropolitain; Hôtel-Dieu de Québec; Université Laval; Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Psoriasis; Placebo; Dosing; Maintenance therapy; Clinical trial; Phases of clinical research; Internal medicine; Chemotherapy; Dermatology; Pathology; Secukinumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02866493,0.001033129,0.003616991,0.0009809607,0.000265023,0.002027185,0.0007085817,0.001031841,0.001986915],"category_scores_gemma":[0.02672868,0.0005485762,0.009865979,0.001350784,0.0005637224,0.001098623,0.0009041973,0.00170171,0.0001561901],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001035818,"about_ca_system_score_gemma":0.001326838,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005910821,"about_ca_topic_score_gemma":0.001124214,"domain_scores_codex":[0.9751893,0.02011256,0.001368581,0.001241598,0.001559871,0.0005280484],"domain_scores_gemma":[0.9760131,0.01511503,0.005450451,0.001620162,0.0009507382,0.0008505977],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.7254717,0.00212093,0.04094207,0.003634602,0.1440054,0.00009887295,0.0001422747,0.0040405,0.003657665,0.0002716337,0.001018409,0.07459596],"study_design_scores_gemma":[0.3765146,0.1679233,0.1757606,0.001116511,0.2548578,0.0003479818,0.0001803157,0.01348975,0.002669061,0.001810993,0.005180891,0.0001481625],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.927954,0.0544133,0.008474301,0.0006261326,0.0002342929,0.003969407,0.002607215,0.0001755352,0.001545782],"genre_scores_gemma":[0.9883159,0.004055819,0.003964947,0.0003123443,0.0001237853,0.001622256,0.001277181,0.00003694567,0.000290754],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02866493,"threshold_uncertainty_score":0.1515965,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07432504716928887,"score_gpt":0.3566753525540663,"score_spread":0.2823503053847775,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}